What Park Ha Biological Technology Actually Is

A Chinese skincare company with 45 beauty stores, about $2.5 million in annual revenue, and roughly $2.4 million in total market value. That is Park Ha Biological Technology (NASDAQ: BYAH). But for one week in July 2025, the market valued this company at over $1 billion.

The stock went from its $4 IPO price to an intraday high of $41.49, then collapsed 93% the next day — erasing roughly $1 billion in market capitalization in a single session. No product launch. No earnings surprise. No material business news at all.

The basic point is that this was not a story about skincare demand. It was a story about what happens when a company lists on Nasdaq with fewer than 5% of its shares available to public traders, and the market plumbing turns into a pressure cooker. A securities class action lawsuit alleges the IPO was intentionally structured that way to make manipulation possible. Whether or not that allegation is proven in court, the mechanism is worth understanding — because this company is one visible example of a pattern that has now cost investors across dozens of firms.

The float is the mechanism.

Park Ha went public on December 27, 2024, selling 1.2 million ordinary shares at $4 each, raising $4.8 million. But after the offering, there were 26.2 million shares outstanding. The public bought less than 5%. Insiders and pre-IPO shareholders held the rest.

A low float means there are very few shares available for public traders to buy and sell. With only 1.2 million shares floating, even modest buying pressure creates outsized price moves. Think of it like a small pond versus a lake: the same amount of water displaced makes a bigger wave. In market terms, 100,000 shares of buying pressure in a 1.2-million-share float is a seismic event. In a normal float, it's background noise.

The IPO prospectus did include boilerplate warnings about "small-float volatility." But the lawsuit alleges the company concealed something much more specific: that the stock was being targeted by a coordinated promotion campaign — WhatsApp groups, social media ads, and impersonators posing as financial advisors — pushing false claims that the stock could rise 200% to 300% and that the company was about to partner with L'Oréal. Neither the L'Oréal rumor nor the price target had any basis in the company's operations or filings.

The company, the lawsuit says, never disclosed that this promotion was happening.

What follows is predictable from the structure.

Beginning around mid-June 2025, the stock started climbing. From a $4 IPO price to $34.99 by June 30. Then to $41.01 on July 7, with an intraday high of $41.49, on more than 1.3 million shares traded — which was itself enormous relative to the public float. The next day, July 8, 2025, the stock fell $38.02 to close at $2.99. Trading volume hit 8.9 million shares — presumably because the people who bought at $30, $35, and $40 were all trying to exit at once.

The company did not issue a press release or statement addressing the unusual trading. The closing price of $2.99 was about 25% below the $4 IPO price.

This is not a unique pattern. A Bloomberg analysis published in January 2026 found that since 2023, roughly $16 billion in market capitalization has evaporated in one- or two-day crashes across approximately 60 new Nasdaq-listed firms. About a quarter of the 250-plus companies that went public on Nasdaq's smallest tier during that period were promoted in chatrooms and subsequently crashed or were suspended by the SEC. The overwhelming majority were Asia-headquartered, with Chinese-linked companies making up the largest share.

One-third of the small Asia-headquartered companies studied showed evidence of stock manipulation, compared to just six non-Asian microcaps. Nasdaq has since proposed tighter rules specifically for Chinese companies and raised its minimum public float requirement.

The gatekeepers matter, too.

The lawsuit names more than just the company. It names CEO Xiaoqiu Zhang, CFO Xiaoyan Zhu, director Li Wang, the auditor (WWC, P.C.), and the IPO underwriters: Dawson James Securities and Boral Capital.

The underwriter question is the one that extends beyond this single company. underwriter D Boral Capital helped take more than 30 firms public, and 10 became subjects of pump-and-dump campaigns. The Bloomberg analysis found that just eight underwriters were responsible for bringing nearly three-quarters of these targeted microcaps to market. The incentive structure is straightforward: the underwriter earns a fee on the IPO and has no financial skin in the game once the shares start trading. They are rewarded for completing the listing, not for preventing the stock from being manipulated weeks or months later.

FINRA has announced a wide-ranging review of underwriters handling small, overseas-based companies. The SEC's chief accountant Jamie Selway told reporters: "Toxic foreign small caps are not welcome here". Nasdaq faces criticism from brokers like Charles Schwab, which argued in a regulatory comment letter that exchange listing standards are "overly lenient" and allow fraud to "snowball".

So the structure is: a company needs a listing. An underwriter needs a fee. An exchange has low barriers. Promoters need a liquid market to sell into. And the retail investor shows up with their brokerage app and a WhatsApp message telling them the stock is about to triple.

The financial machine works because each participant's incentives align until the price collapses — and then they don't.

What the company looks like now.

Park Ha is still trading on Nasdaq, but the story has moved into a different chapter. The company changed its ticker from PHH to BYAH in October 2025, saying the change was to avoid confusion with a delisted company that used the same symbol. It completed a $2.45 million public offering in January 2026 at $0.112 per unit, and a $2 million registered direct offering in June 2026. It has also done a 1-for-8 reverse stock split — a move that changes the share count but not the market cap, and that tends to signal the company is trying to meet exchange minimum-price requirements.

The company is also trying to reposition itself. In mid-2026 it announced partnerships with Cloud Factory Technology Holdings and Star Plus Legend Group, approval to open an Amazon North America store, and membership with the Personal Care Products Council.

These are real enough announcements, but they also belong in context. The company still generates about $2.5 million in annual revenue, and reported a net loss of roughly $24.4 million, and still has only 3 directly operated stores plus 39 franchisees in China. A $2.4 million market capitalization means the company is worth, in aggregate, less than some underwriters' IPO fees.

The investment case — or lack of one.

This is not an article about whether you should buy or sell BYAH. It's an article about what BYAH actually is, because the distinction between a company you can evaluate and a company that functions as a financial trap is one of the most useful distinctions an investor can make.

The lawsuit has a class period running from December 27, 2024 through July 8, 2025, and a lead plaintiff deadline of September 28, 2026. The case has not been certified. No court has yet found that the IPO was intentionally designed for manipulation, or that the company knew about the promotion campaign. The allegations are serious but they are allegations.

What is documented, though, is the structure: a less-than-5% public float on a Nasdaq listing, an underwriter who has been linked to multiple similar outcomes, a post-IPO price surge with no business catalyst, a 93% single-day collapse, and a company that now trades at a fraction of its IPO price with no visible path to profitability. The financial machine — low float, coordinated promotion, concentrated insiders, underwriter who collected their fee — is the same one that has appeared across dozens of companies.

For a retail investor, the useful takeaway is structural, not about this particular stock. A Nasdaq listing is not itself a quality filter. A company can be on Nasdaq, have an IPO prospectus, use a registered underwriter, and still be fundamentally indistinguishable from a financial instrument designed to be pushed and dumped. The float is one of the first numbers to check. The underwriter is another. And the gap between what the company sells and what the stock price implies it's worth is the third.

When all three point in the same direction — tiny float, underwriter with a track record of troubled listings, and a stock price that makes no sense relative to revenue — the most rational position is not conviction. It's staying away.